Latest From Vaximm AG
This week's announcements include Novartis's replacement for Vas Narasimhan as head of global development, GlaxoSmithKline's new head of worldwide business development for pharmaceuticals research & development, new board members at Celgene, an interim CEO at Nordic Nanovector, and changes at Vectura, PureTech Health and Exicure.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.
Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.
Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm AG, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about how the company is differentiating itself in the crowded immuno-oncology development space. Vaximm is also looking for pharma partners with checkpoint inhibitors to advance its oral T-cell immunotherapies.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Vaximm AG
- Senior Management
- Matthias Schroff, PhD, CEO
- Contact Info
Phone: 61 271 2042
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.